Enorama Pharma AB (publ)

Stockholm Stock Exchange ERMA.ST

Enorama Pharma AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2023

Enorama Pharma AB (publ) Return on Capital Employed (ROCE) is NA for the year ending December 31, 2023. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Enorama Pharma AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -112.29%, a -63.63% change year over year.
Enorama Pharma AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -68.63%, a 33.51% change year over year.
Enorama Pharma AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -103.22%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Stockholm Stock Exchange: ERMA.ST

Enorama Pharma AB (publ)

CEO	Mr. Daniel Schroder
IPO Date	June 10, 2016
Location	Sweden
Headquarters	Södergatan 3
Employees	5
Sector	Health Care
Industries Pharmaceuticals Tobacco

Description

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in Malmö, Sweden.

Key trends

Past 5 years